Takeda Pharmaceutical Co Ltd
TSE:4502

Watchlist Manager
Takeda Pharmaceutical Co Ltd Logo
Takeda Pharmaceutical Co Ltd
TSE:4502
Watchlist
Price: 4 483 JPY -0.27% Market Closed
Market Cap: 7.1T JPY

Takeda Pharmaceutical Co Ltd
Interest Income Expense

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Takeda Pharmaceutical Co Ltd
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
Takeda Pharmaceutical Co Ltd
TSE:4502
Interest Income Expense
-ÂĄ147.7B
CAGR 3-Years
-4%
CAGR 5-Years
3%
CAGR 10-Years
-22%
Daiichi Sankyo Co Ltd
TSE:4568
Interest Income Expense
ÂĄ37B
CAGR 3-Years
N/A
CAGR 5-Years
30%
CAGR 10-Years
16%
Otsuka Holdings Co Ltd
TSE:4578
Interest Income Expense
ÂĄ35.5B
CAGR 3-Years
0%
CAGR 5-Years
33%
CAGR 10-Years
11%
S
Shionogi & Co Ltd
TSE:4507
Interest Income Expense
ÂĄ49.8B
CAGR 3-Years
2%
CAGR 5-Years
9%
CAGR 10-Years
8%
Chugai Pharmaceutical Co Ltd
TSE:4519
Interest Income Expense
ÂĄ182m
CAGR 3-Years
-55%
CAGR 5-Years
N/A
CAGR 10-Years
-6%
Astellas Pharma Inc
TSE:4503
Interest Income Expense
-ÂĄ13.2B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Takeda Pharmaceutical Co Ltd
Glance View

In the ever-evolving landscape of global pharmaceuticals, Takeda Pharmaceutical Co Ltd. stands as a robust and adaptive entity, blending a rich heritage with bold innovation. Originating from Japan, Takeda's journey began over two centuries ago, carving its niche by focusing on value-driven and research-led approaches in the pharmaceutical industry. With its headquarters in Tokyo, the company has fortified its position as one of the global leaders, largely due to its emphasis on research and development that spans across cutting-edge areas such as oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies. This innovation-centric strategy is not just a nod to the future, but a crucial component that allows Takeda to address pressing health challenges worldwide, continually expanding its pipeline with transformative therapies. Takeda's commercial model revolves around its diverse therapeutic portfolio and strategic collaborations, which are instrumental in capturing growth across various markets. By leveraging its scientific expertise and expanding technological capabilities, the company advances its core business segments while integrating augmented biotechnology solutions through strategic acquisitions and partnerships. The absorption of Shire, a prominent biotechnology firm, stands as a hallmark of Takeda's commitment to enhancing its presence in rare diseases and plasma-derived therapies, thereby widening its global footprint. This focus not only fuels revenue generation from innovative products but also ensures a multidimensional approach to market entry across pivotal regions. Through balancing its inventive drive with operational efficiency, Takeda efficiently monetizes its products, securing its status as a formidable player in the pharmaceutical domain.

Intrinsic Value
5 092.97 JPY
Undervaluation 12%
Intrinsic Value
Price

See Also

What is Takeda Pharmaceutical Co Ltd's Interest Income Expense?
Interest Income Expense
-147.7B JPY

Based on the financial report for Sep 30, 2025, Takeda Pharmaceutical Co Ltd's Interest Income Expense amounts to -147.7B JPY.

What is Takeda Pharmaceutical Co Ltd's Interest Income Expense growth rate?
Interest Income Expense CAGR 10Y
-22%

Over the last year, the Interest Income Expense growth was 16%. The average annual Interest Income Expense growth rates for Takeda Pharmaceutical Co Ltd have been -4% over the past three years , 3% over the past five years , and -22% over the past ten years .

Back to Top